No.3 .Tazemetostat- (TAZVERIK)- (Jan 2020) 

PATIENT COUNSELING INFORMATION

Instruct the patient to read the FDA-approved patient labeling (Medication Guide).

Secondary Malignancies                                                                                      Advise patients of the increased risk of secondary malignancies, including AML, MDS, and T-LBL.

Advise patients to inform their healthcare provider if they experience fatigue, easy bruising, fever, bone pain, or paleness 

Embryo-Fetal Toxicity                                                                                           Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

Advise females to inform their healthcare provider of a known or suspected pregnancy 

Advise females of reproductive potential to use effective non-hormonal contraception during treatment with TAZVERIK and for 6 months after the final dose 

Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose 

Lactation                                                                                                               Advise women not to breastfeed during treatment with TAZVERIK and for 1 week after the final dose 

Drug Interactions

Advise patients and caregivers to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products. Inform patients to avoid St. John’s wort, grapefruit, and grapefruit juice while taking TAZVERIK 

Manufactured for: Epizyme, Inc. 400 Technology Square Cambridge, MA 02139 ©2020 Epizyme, Inc.